Skip to main content
Premium Trial:

Request an Annual Quote

VA, Sanford Health to Offer Free PGx Testing to 250K Vets

NEW YORK (GenomeWeb) – The US Department of Veterans Affairs and Sioux Falls, South Dakota-headquartered healthcare system Sanford Health today announced they will provide pharmacogenetic testing to up to 250,000 veterans.

The program, which will provide PGx testing at no cost to veterans, is supported via a $25 million gift from philanthropist Denny Sanford. Sanford Health also fundraised matching contributions. The pilot program will launch at one site in Durham, North Carolina and will initially test vets who are cancer survivors. By 2022, the plan is to provide testing to 250,000 veterans and expand to 125 sites.

According to Deepak Voora, director of the VA PHASeR (Pharmacogenomics Action for Cancer Survivorship) Program and an associate professor at Duke University, this will be the largest PGx testing program in the country. The test results will be used to guide decisions about treatments for a variety of conditions, including mental health and cardiovascular diseases. The data collected within the program will also facilitate research.

Veterans will be able to get tested at their local VA facility. Sanford will analyse the results at its South Dakota Imagenetics facility. As the program expands, it will also include genetic counseling.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.